Table 1.
Demographic, Behavioral, and Clinical Characteristics of Participants
| Characteristic* | Participants With Valid Liver Fibrosis Measures (n = 1176) | Participants Without Valid Liver Fibrosis Measures (n = 84) |
|---|---|---|
| Median study visits (IQR), n | 7 (4–10) | 3 (2–8) |
| Median age (IQR), y | 49 (43–53) | 47 (42–54) |
| Women, n (%) | 371 (32) | 47 (56) |
| Black, n (%) | 997 (85) | 69 (82) |
| Median BMI (IQR), kg/m2 | 25 (22–28) | 33 (28–42) |
| Injection drug use, n (%) | ||
| None | 554 (47) | 38 (45) |
| Less than daily | 264 (22) | 24 (29) |
| Daily or more | 356 (30) | 22 (26) |
| Ever used alcohol daily, n (%)† | 412 (35) | 23 (27) |
| Median ALT level (IQR), IU/L | 32 (20–52) | 29 (21–45) |
| HCV RNA level (IQR), log10 IU/mL‡ | 6.08 (5.08–6.58) | 5.49 (ND–6.50) |
| HIV infection, n (%) | 394 (34) | 24 (29) |
| Median CD4 count (IQR), × 109 cells/L | 0.287 (0.148–0.458) | 0.257 (0.178–0.512) |
| Median nadir CD4 count (IQR), × 109 cells/L | 0.175 (0.075–0.282) | 0.258 (0.164–0.420) |
| Median HIV RNA level (IQR), log10 copies/mL | 3.0 (<2.6–4.5) | 2.6 (<2.6–4.0) |
ALT = alanine aminotransferase; BMI = body mass index; HCV = hepatitis C virus; IQR = interquartile range; ND = not detected.
Data refer to measurement at the baseline visit or the ptevious 6-mo period. Baseline visit was defined as the first visit with valid liver fibrosis measurement or, for those with no valid liver fibrosis measurement, the first visit after February 2006 when FibroScan (Echosens, Paris, France) was incorporated into the ALIVE (AIDS Linked to the IntraVenous Experience) study protocol.
Indicates self-reported use during cumulative study visits before the first FibroScan measurement (baseline).
Data were missing in 10 (1%) and 53 (32%) of participants with and without valid liver fibrosis measurements, respectively.